RaySearch Laboratories AB (publ) announces that Oslo University Hospital (Norwegian: Oslo universitetssykehus) has awarded a significant tender for treatment planning system RayStation®* for photon therapy as well as for use at Norway's first national proton therapy center. The tender encompasses implementation and training, as well as options for three further hospitals in the country.
[Oslo University Hospital logo]
Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority and an OECI-accredited Comprehensive Cancer Center (CCC). Each year, more than 1.2 million patient treatments are carried out at the hospital, which is the largest of its kind in Scandinavia. The Department of Oncology is involved in intensive research into new cancer treatment methods and has a total of 17 medical linear accelerators in operation, making it one of the largest radiation-therapy clinics in the world.
The tender awarded for RayStation addresses future needs for planning for photon therapy, as well as for proton therapy at the country's first national proton therapy center. Oslo University Hospital recently procured three Varian ProBeam® proton gantries for the center - presently under construction - with the goal to start treating patients in 2023. The principal treatment planning system currently in use is the Oncentra External Beam from Elekta, which has an end-of-life status in May 2020 and will be replaced in the first implementation phase.
Factors informing the evaluation committee's decision to award the tender to RaySearch fall into five broad categories: Improved quality of care (1), Improved clinical efficiency (2), Improved efficiency through automation (3), Ensure patient information security (4) and Meet society's expectations in terms of research and continuous development (5). The committee highlighted the smooth adaptive planning workflow in RayStation and features that will result in more-efficient treatment planning overall.
Prof. Sigbjørn Smeland, Head Division of Cancer Medicine and Director of Oslo University Hospital, CCC, says: "One the main objectives of this tender was to make a significant contribution to the consolidation of treatment planning at Oslo University Hospital - and at the future proton therapy center. We expect it to be more efficient for us to operate a single system. Proficiency and precision are critical elements of our work and we need tools that make workflows smoother without compromising quality of care. I am excited about the potential of machine-learning capabilities in RayStation to give us more time to spend with our patients and to focus our resources on giving them high-quality care."
Johan Löf, founder and CEO, RaySearch, says: "Oslo University Hospital is a leading name within cancer research and treatment. It is therefore gratifying that such a prestigious and forward-thinking institution has opted to use RayStation for its treatment planning of radiation therapy. I look forward to close collaboration between RaySearch and the highly skilled oncology teams in Oslo."
The scope of the tender includes the option to enter into contracts for RayStation at Hospital of Southern Norway (Sørlandet sykehus), University Hospital of North Norway HF (Universitetssykehuset Nord-Norge HF) and St. Olav's University Hospital (St. Olavs Universitetssykehuset).
For further information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
About Oslo University Hospital
Oslo University Hospital is owned by the South-Eastern Norway Regional Health Authority (HSØ) and delivers specialist healthcare services to patients all over Norway. Oslo University Hospital is Norway's largest hospital with around 20,000 employees and is responsible for a significant proportion of the medical research and the education of medical personnel in the country. More information about Oslo University Hospital can be found at https://oslo-universitetssykehus.no
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare®*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.
* Subject to regulatory clearance in some markets.
More information about RaySearch is available at www.raysearchlabs.com
(c) 2020 Cision. All rights reserved., source Press Releases - English